Abdoreza Ghoreishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abdoreza Ghoreishi has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Alireza Khosravi
Clinical Immunology Research Center, Department of Neurology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
2 shared publications- Athena Sharifi-Razavi
Clinical Research Development Unit of Bu-Ali Sina Hospital, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 shared publications Babak Zamani
Department of Neurology, Iran University of Medical Sciences, Tehran, Iran
2 shared publications- Mehdi Maghbooli
Zanjan University of Medical Sciences, Vali-e-Asr University Hospital
2 shared publications Mohammad Hossein Harirchian
Iranian Center of Neurological Research (ICNR), Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsA. Rezvanizadeh
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Elsevier in SSRN Electronic Journal
Intravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry
Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.
- 28 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntravenous Thrombolysis for Acute Ischemic Stroke Across the Middle East and North Africa (2021–2023): Results from the SITS-MENA Registry
Background: Intravenous thrombolysis (IVT) for acute ischemic stroke in the Middle-East and North African (MENA) countries has increased in the last decade, but long-term outcomes and quality of care are less well studied. Methods: This was a prospective observational study to examine 3-month outcomes of IVT-treated patients in MENA stroke units using the SITS Registry. Findings: There were 2768 patients in MENA and 7163 patents in non-MENA treated with IVT and registered in SITS between August 2021 and September 2023. Compared to non-MENA, MENA patients were younger (65 vs 72 years-old), had higher NIH Stroke Scale scores at baseline (11 vs 9) and shorter door-to-needle times (30 vs 54 min). The most common risk factors in MENA were hypertension (64.9 vs 69.8 %) and diabetes (30.8 vs 20.1%). Functional independence at 3 months was similar (56.6% vs 57.7%); however, mortality at 7 and 30 days was significantly higher in MENA (8.3% vs 5.3% and 20.7 vs 14.5%). Symptomatic intracranial hemorrhage rates were low in both groups (<1.2% per SITS-MOST). Early mortality rates related to stroke were comparable (56.7 vs 59.2%) but early deaths caused by myocardial infarction, pneumonia, pulmonary embolism and sepsis were more frequent in MENA (14.2 vs 4.6%, 6.7 vs 4.6%, 1.5 vs 0.4% and 3 vs 1.8%). Interpretation: The overall mortality of IVT-treated patients was increased in MENA at 7 and 90 days post-stroke. Differences in risk factors at baseline may account for mortality but the treatment of medical complications in MENA stroke units warrants further study.
- Open Access
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 28-38
Thrombolysis Treatment in Patients Who Are Awake and Have an Unknown Duration of Stroke Receiving Effective and Safe Treatment or Who Are Futile and At Risk: A Study-Based SITS
Background: Stroke is a leading cause of death worldwide, with approximately 800,000 new cases and 140,000 deaths annually in the United States. Intravenous tissue plasminogen activator (IV tPA) is the standard treatment for acute ischemic stroke (AIS) within a 4.5-hour window. Wake-up stroke (WUS), where the exact onset time is unknown, poses ...
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 28-38
Open AccessThrombolysis Treatment in Patients Who Are Awake and Have an Unknown Duration of Stroke Receiving Effective and Safe Treatment or Who Are Futile and At Risk: A Study-Based SITS
Background: Stroke is a leading cause of death worldwide, with approximately 800,000 new cases and 140,000 deaths annually in the United States. Intravenous tissue plasminogen activator (IV tPA) is the standard treatment for acute ischemic stroke (AIS) within a 4.5-hour window. Wake-up stroke (WUS), where the exact onset time is unknown, poses ...
- Open Access
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 73-80
Cefaly Neurostimulation Therapy For Intractable Migraine Patients
Background and Objective: Migraine is a common neurological disorder affecting one billion people worldwide, causing disability, reduced quality of life, and high economic costs. Medical treatments have often limited efficacy and side effects. Non-pharmacological options such as trigeminal nerve stimulation with devices such as Cefaly® offer alternatives. This study assesses effectiveness ...
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 73-80
Open AccessCefaly Neurostimulation Therapy For Intractable Migraine Patients
Background and Objective: Migraine is a common neurological disorder affecting one billion people worldwide, causing disability, reduced quality of life, and high economic costs. Medical treatments have often limited efficacy and side effects. Non-pharmacological options such as trigeminal nerve stimulation with devices such as Cefaly® offer alternatives. This study assesses effectiveness ...
- 22 March 2024
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 299 (1) , 1-11
Identification of four novel mutations in VSP13A in Iranian patients with Chorea-acanthocytosis (ChAc)
Chorea-acanthocytosis (ChAc) is a rare autosomal recessive neurodegenerative disorder characterized by a variety of involuntary movements, predominantly ch
- 22 March 2024
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 299 (1) , 1-11
Identification of four novel mutations in VSP13A in Iranian patients with Chorea-acanthocytosis (ChAc)
Chorea-acanthocytosis (ChAc) is a rare autosomal recessive neurodegenerative disorder characterized by a variety of involuntary movements, predominantly ch
- 20 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106121
Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
- 20 September 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (12) , 106121
Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative
- 1 January 2021
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 29 (132) , 14-20
Biofeedback: An Effective Add-on Treatment for Migraine Headache Alongside Medication Therapy
Background & Objective: Migraine is an occasional headache that represents neurological and gastrointestinal symptoms, as well as changes in the autonomic nervous system. Biofeedback is a non-pharmacological technique used to treat migraine headaches and is proven to reduce headaches and improve performance. The present study aimed to compare the efficacy of ...
- 1 January 2021
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 29 (132) , 14-20
Biofeedback: An Effective Add-on Treatment for Migraine Headache Alongside Medication Therapy
Background & Objective: Migraine is an occasional headache that represents neurological and gastrointestinal symptoms, as well as changes in the autonomic nervous system. Biofeedback is a non-pharmacological technique used to treat migraine headaches and is proven to reduce headaches and improve performance. The present study aimed to compare the efficacy of ...
- Open Access
- 22 December 2020
- Published by Knowledge E DMCC in Current Journal of Neurology
- Vol. 19 (2) , 53-58
The association between serum 25-hydroxyvitamin D level and subclinical atherosclerosis in healthy population
Background: Subclinical atherosclerosis is the asymptomatic phase of carotid atherosclerosis, and its early diagnosis is important to prevent cerebrovascular diseases. Although the vitamin D plays a role in the structure of vessels, the association between the serum level of vitamin D and subclinical atherosclerosis has not been well-studied. We aimed to investigate the association between serum vitamin D level and carotid artery intima-media thickness (CIMT) in Iranian population. Methods: One hundred individuals with the age range from 20 to 50 years with no history of cardiovascular risk factors were selected for the analysis. Measurements of serum 25-hydroxyvitamin D3 [25(OH) D3] concentration and CIMT were made. Confounding factors such as diabetes, hypertension (HTN), smoking, alcohol, tobacco, dyslipidemia, cardiovascular disease (CVD), high body mass index (BMI), history of drug intake especially calcium, vitamin D, statins, and anti-hypertensive drugs were considered and then excluded from our study. Results: The mean serum vitamin D level was 15.55 ± 0.42 ng/ml, whereas in the increased intima-media thickness (IMT), it was 12.50 ± 9.50 ng/ml. 55% of the subjects were diagnosed with subclinical atherosclerosis (IMT ≥ 0.75 mm). Mean IMT was 0.74 ± 0.12 mm; however, it was higher (0.86 ± 0.30) in severe vitamin D deficiency group. The analysis showed an association between serum 25(OH) D3 level and CIMT (P = 0.002). 44% of those participants with subclinical atherosclerosis had also a severe vitamin D deficiency, while only 13% of normal people had a severe vitamin D deficiency. Also, a correlation was observed between severe vitamin D deficiency and the presence of plaque or higher IMT. Conclusion: Serum 25(OH) D3 level was inversely correlated with CIMT in our investigated subjects with no cardiovascular risk factor.
- 22 December 2020
- Published by Knowledge E DMCC in Current Journal of Neurology
- Vol. 19 (2) , 53-58
Open AccessThe association between serum 25-hydroxyvitamin D level and subclinical atherosclerosis in healthy population
Background: Subclinical atherosclerosis is the asymptomatic phase of carotid atherosclerosis, and its early diagnosis is important to prevent cerebrovascular diseases. Although the vitamin D plays a role in the structure of vessels, the association between the serum level of vitamin D and subclinical atherosclerosis has not been well-studied. We aimed to investigate the association between serum vitamin D level and carotid artery intima-media thickness (CIMT) in Iranian population. Methods: One hundred individuals with the age range from 20 to 50 years with no history of cardiovascular risk factors were selected for the analysis. Measurements of serum 25-hydroxyvitamin D3 [25(OH) D3] concentration and CIMT were made. Confounding factors such as diabetes, hypertension (HTN), smoking, alcohol, tobacco, dyslipidemia, cardiovascular disease (CVD), high body mass index (BMI), history of drug intake especially calcium, vitamin D, statins, and anti-hypertensive drugs were considered and then excluded from our study. Results: The mean serum vitamin D level was 15.55 ± 0.42 ng/ml, whereas in the increased intima-media thickness (IMT), it was 12.50 ± 9.50 ng/ml. 55% of the subjects were diagnosed with subclinical atherosclerosis (IMT ≥ 0.75 mm). Mean IMT was 0.74 ± 0.12 mm; however, it was higher (0.86 ± 0.30) in severe vitamin D deficiency group. The analysis showed an association between serum 25(OH) D3 level and CIMT (P = 0.002). 44% of those participants with subclinical atherosclerosis had also a severe vitamin D deficiency, while only 13% of normal people had a severe vitamin D deficiency. Also, a correlation was observed between severe vitamin D deficiency and the presence of plaque or higher IMT. Conclusion: Serum 25(OH) D3 level was inversely correlated with CIMT in our investigated subjects with no cardiovascular risk factor.
- Open Access
- 23 September 2019
- Published by Maad Rayan Publishing Company in International Clinical Neuroscience Journal
- Vol. 6 (4) , 140-145
Effect of Nanomicelle Curcumin on Quality of Life and Sleep in Patients With Parkinson’s Disease: A Double-Blind, Randomized, and PlaceboControlled Trial
Background: Considering the evidence indicating the neuronal protective effects of curcumin in previous studies, this double-blind, randomized, placebo-controlled, and parallel-group trial was aimed at exploring the possible nanomicelle curcumin (SinaCurcumin®, nano-micellar soft gel)- mediated impact on sleep, fatigue, and quality of life (QoL) in patients with Parkinson’s disease (PD). Methods: A sample of 50 PD patients were recruited and randomly divided into experimental (25) and control groups (25). Sleep quality, fatigue, and QoL were assessed based on the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Parkinson’s Disease Questionnaire–39 (PDQ-39), respectively, at the beginning and the end of the study. The groups were treated for three months by 80 mg of nano-micellar soft gel twice a day. Results: Nanomicelle curcumin significantly increased sleep quality and QoL compared with placebo (P values=0.0001 and 0.0002, respectively) in PD patients. This significant difference has not influenced by the duration of the disease, the severity of disease progression (Hoehn & Yahr scale), and the cumulative dose of levodopa. This supplement did not have a significant effect on the fatigue severity of patients compared to placebo. Conclusion: It has proposed that the nanomicelle curcumin can be used to improve sleep quality and QoL in PD patients.
- 23 September 2019
- Published by Maad Rayan Publishing Company in International Clinical Neuroscience Journal
- Vol. 6 (4) , 140-145
Open AccessEffect of Nanomicelle Curcumin on Quality of Life and Sleep in Patients With Parkinson’s Disease: A Double-Blind, Randomized, and PlaceboControlled Trial
Background: Considering the evidence indicating the neuronal protective effects of curcumin in previous studies, this double-blind, randomized, placebo-controlled, and parallel-group trial was aimed at exploring the possible nanomicelle curcumin (SinaCurcumin®, nano-micellar soft gel)- mediated impact on sleep, fatigue, and quality of life (QoL) in patients with Parkinson’s disease (PD). Methods: A sample of 50 PD patients were recruited and randomly divided into experimental (25) and control groups (25). Sleep quality, fatigue, and QoL were assessed based on the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Parkinson’s Disease Questionnaire–39 (PDQ-39), respectively, at the beginning and the end of the study. The groups were treated for three months by 80 mg of nano-micellar soft gel twice a day. Results: Nanomicelle curcumin significantly increased sleep quality and QoL compared with placebo (P values=0.0001 and 0.0002, respectively) in PD patients. This significant difference has not influenced by the duration of the disease, the severity of disease progression (Hoehn & Yahr scale), and the cumulative dose of levodopa. This supplement did not have a significant effect on the fatigue severity of patients compared to placebo. Conclusion: It has proposed that the nanomicelle curcumin can be used to improve sleep quality and QoL in PD patients.
- Open Access
- 17 February 2019
- Published by Biomedpress in Biomedical Research and Therapy
- Vol. 6 (2) , 2996-3002
Impaired oxidative-antioxidative balance during migraine attack
Background: Recent evidence has suggested that oxidative stress may play a role in the pathophysiology of migraine. In this study, we aimed to evaluate the oxidative-antioxidative status in sera of migraine patients from an Iranian population during migraine attacks. Methods: This study recruited 46 migraine patients with or without aura and 45 sex- and age-matched healthy controls. The levels of protein carbonyl (PC), malondialdehyde (MDA) and total oxidants status (TOS) were measured as the indicators of oxidative stress. The levels of total thiols (T-SH), reduced glutathione (GSH) and total antioxidant capacity (TAC) were determined as markers of antioxidant status. Oxidative stress index (OSI) was calculated by dividing TOS to TAC. Results: The serum levels of MDA (4.10 +/- 0.70 vs. 3.20 +/- 0.62, P = 0.003), TOS (18.46 +/- 4.06 vs. 16.21 +/- 3.67, P = 0.007) and OSI (1.54 +/- 0.60 vs. 1.22 +/- 0.46, P = 0.006) were significantly higher in migraine group compared to controls, however, no statistically significant differences of PC levels were found between migraine patients and controls (0.615 +/- 0.161 vs. 0.517 +/- 0.126, P = 0.1). In contrast, the levels of T-SH (273 +/- 51.71 vs. 310.88 +/- 53.32, P = 0.001), GSH (28.08 +/- 6.20 vs. 32.13 +/- 5.8, P = 0.002) and TAC (1.27 +/- 0.226 vs. 1.41 +/- 0.26, P = 0.01) were significantly lower in migraine patients compared to healthy controls. Conclusion: Our study showed higher levels of oxidative stress and lower levels of antioxidant status in migraine group compared to controls, which indicates the possible role of oxidative stress in triggering migraine attacks.
- 17 February 2019
- Published by Biomedpress in Biomedical Research and Therapy
- Vol. 6 (2) , 2996-3002
Open AccessImpaired oxidative-antioxidative balance during migraine attack
Background: Recent evidence has suggested that oxidative stress may play a role in the pathophysiology of migraine. In this study, we aimed to evaluate the oxidative-antioxidative status in sera of migraine patients from an Iranian population during migraine attacks. Methods: This study recruited 46 migraine patients with or without aura and 45 sex- and age-matched healthy controls. The levels of protein carbonyl (PC), malondialdehyde (MDA) and total oxidants status (TOS) were measured as the indicators of oxidative stress. The levels of total thiols (T-SH), reduced glutathione (GSH) and total antioxidant capacity (TAC) were determined as markers of antioxidant status. Oxidative stress index (OSI) was calculated by dividing TOS to TAC. Results: The serum levels of MDA (4.10 +/- 0.70 vs. 3.20 +/- 0.62, P = 0.003), TOS (18.46 +/- 4.06 vs. 16.21 +/- 3.67, P = 0.007) and OSI (1.54 +/- 0.60 vs. 1.22 +/- 0.46, P = 0.006) were significantly higher in migraine group compared to controls, however, no statistically significant differences of PC levels were found between migraine patients and controls (0.615 +/- 0.161 vs. 0.517 +/- 0.126, P = 0.1). In contrast, the levels of T-SH (273 +/- 51.71 vs. 310.88 +/- 53.32, P = 0.001), GSH (28.08 +/- 6.20 vs. 32.13 +/- 5.8, P = 0.002) and TAC (1.27 +/- 0.226 vs. 1.41 +/- 0.26, P = 0.01) were significantly lower in migraine patients compared to healthy controls. Conclusion: Our study showed higher levels of oxidative stress and lower levels of antioxidant status in migraine group compared to controls, which indicates the possible role of oxidative stress in triggering migraine attacks.